finerenone – Medxy AI

Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety

By MedXY 11/09/2025

The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type 2 diabetes trials and a manageable hyperkalemia signal.

Cardiology Specialties

Finerenone Efficacy and Safety Across Frailty Levels in Heart Failure: Insights from the FINEARTS-HF Trial

By MedXY 09/13/2025

This analysis of the FINEARTS-HF trial reveals that finerenone reduces cardiovascular death and heart failure worsening regardless of frailty status, without increasing adverse events, supporting its use in frail patients with HFmrEF or HFpEF.

Cardiology news Specialties

Diuretic-Sparing Potential of Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from FINEARTS-HF

By MedXY 08/19/2025

Finerenone consistently reduces heart failure events and allows reduction of loop diuretic dosages without impacting new loop diuretic initiation, demonstrating a diuretic-sparing effect in HFmrEF/HFpEF patients.

Diabetes & Endocrinology Nephrology news Specialties

Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial

By MedXY 08/13/2025

The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818 diverse participants.

Clinical Updates Diabetes & Endocrinology Nephrology news Specialties

Dual Renal Protection: Finerenone Plus Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

By MedXY 08/09/2025

Combining finerenone with empagliflozin provides superior reduction in albuminuria for patients with chronic kidney disease and type 2 diabetes, without increased adverse events.